Unlocking the Potential of PI3K Inhibition in CLL

释放 PI3K 抑制在 CLL 中的潜力

• 批准号: 9883758
• 负责人: Jennifer R Brown
• 金额: $ 57.11万
• 依托单位: DANA-FARBER CANCER INST
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-03-01 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9883758
• 关键词: 1-Phosphatidylinositol 3-Kinase; Affect; Apoptosis; Autoimmune Process; Autoimmunity; B-Lymphocytes; Biochemical; Biological Assay; Biology; Bone Marrow; CD4 Positive T Lymphocytes; Catalytic Domain; Cell physiology; Cells; Characteristics; Clinic; Clinical; Clinical Trials; Colitis; Combined Modality Therapy; Data; Development; Disease; Disease remission; Drug usage; Enrollment; Evaluation; Evolution; Exposure to; FDA approved; Generations; Genetic; Genetic Models; Genomics; Goals; Grant; Hepatitis; Human; Immune; Immune system; Immuno-Chemotherapy; Immunologics; In Vitro; Individual; Lead; Malignant Neoplasms; Mediating; Mus; North America; Oral; Pathway interactions; Patient Care; Patient Selection; Patients; Pattern; Pharmaceutical Preparations; Pharmacology; Phosphotransferases; Protein Isoforms; Pulmonary Inflammation; Receptors, Antigen, B-Cell; Refractory; Regimen; Regulatory T-Lymphocyte; Relapse; Resistance; Risk; Role; Safety; Selection for Treatments; Signal Pathway; Signal Transduction; Solid; Solid Neoplasm; Stimulus; T-Lymphocyte; Time; Toxic effect; Up-Regulation; Work; adult leukemia; anti-cancer; base; cohort; design; effector T cell; experimental study; high risk; immune activation; immune function; immunoregulation; inhibitor/antagonist; kinase inhibitor; knock-down; leukemia; mouse model; new therapeutic target; next generation; novel therapeutics; patient population; phosphatidylinositol 3-kinase gamma; pre-clinical; prospective; randomized trial; relapse patients; resistance mechanism; response; targeted treatment; transcriptomics

Project Summary CLL is the most common leukemia of adults in North America and remains incurable. Recent discovery of targeted oral kinase inhibitors of the B cell receptor signaling pathway is transforming the therapy of CLL, but challenges remain. Individually none of these drugs is curative, and approximately 30% of patients discontinue for toxicity despite good disease response. The PI3K p110δ inhibitors include the first generation FDA approved drug idelalisib, as well as duvelisib, a PI3K γ and δ inhibitor currently in registration trials. The PI3Kδ inhibitors have a pattern of toxicity that includes hepatitis, colitis and pneumonitis. We have two ongoing clinical trials in CLL patients, one idelalisib based and one duvelisib based, in which we have described these toxicities to be immune-mediated. We have further shown that this toxicity associates with a decrease in T regulatory cells, which could also enhance efficacy and decrease risk of solid tumors in these patients. In this grant in Specific Aim 1 we propose to deepen these observations, characterizing the T regulatory and T effector landscape of CLL during therapy with PI3Kδ inhibitors in relation to observed toxicities, with the goal of identifying clinical and immunologic predictors of toxicity and efficacy. We will further perform in vitro functional assays to assess the impact of PI3Kδ inhibition on the suppressive function of T regulatory cells, the activation capacity of T effector cells and the in vitro differentiation potential of naïve CD4+ T cells. In Specific Aim 2 we will assess the impact of PI3Kδ knockdown on the Eμ-TCL1 mouse model of CLL in terms of disease development, autoimmune toxicity and T cell milieu. These experiments will focus on the mouse kinase dead genetic model but will also assess pharmacologic inhibitors. Aims 1 and 2 will therefore elucidate the fundamental biology of PI3Kδ selective inhibition in humans and mice and enable us to identify predictors of toxicity and efficacy that will optimize patient selection for these drugs. In Specific Aim 3, we will characterize the mechanisms of sensitivity and resistance to PI3Kδ inhibition. Our preliminary data implicate genetic and/or biochemical upregulation of the ERK pathway in patients who are or become resistant to PI3Kδ inhibition. We therefore propose to perform direct mechanistic studies of the impact of ERK pathway activation on PI3Kδ resistance in vitro. We will also perform additional discovery by studying patients enrolled on these two prospective clinical trials at baseline, during remission and at time of acquired resistance, including genomic, transcriptomic and signaling evaluation. This previously untreated uniform patient population represents an ideal homogeneous cohort that will allow us to understand these mechanisms much more effectively than a heterogeneous relapsed cohort. This project will therefore represent a major advance in the understanding of the biology of PI3Kδ inhibition in humans, in terms of its significant immunologic effects and mechanisms of resistance, all of which will allow optimal patient selection for this therapy and may even lead to expanded use of PI3Kδ inhibition in other cancers, based on its immunoregulatory function.

项目总结